CTLA4, AlpHcAbs® Human Alpaca Monoclonal Antibody
cat.: HA710327
| Product Type: | Alpaca monoclonal VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation), primary antibodies |
|---|---|
| Species reactivity: | Human |
| Applications: | ELISA, FC |
| Clonality: | Monoclonal |
| Form: | Liquid |
| Storage condition: | Store at –20 ℃, (Avoid freeze / thaw cycles), Stable for 12 months at -20℃ |
| Storage buffer: | Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol |
| Concentration: | 1ug/ul |
| Purification: | Immunogen affinity purified. |
| Isotype: | VHH domain of alpaca IgG2b/2c fused to Human IgG1 Fc(mutation) |
| Immunogen: | Recombinant human CTLA4 |
| Subcellular location: | Cell membrane |
| Recommended Dilutions:
ELISA FC |
1:4,000-1:10,000 1:200-1:1,000 |
| Uniprot #: | SwissProt: P16410 Human |
| Alternative names: | ALPS5 CD 152 CD CD152 CD152 antigen CD152 isoform Celiac disease 3 CELIAC3 CTLA 4 CTLA-4 CTLA4 CTLA4_HUMAN Cytotoxic T cell associated 4 Cytotoxic T lymphocyte antigen 4 Cytotoxic T lymphocyte associated 4 Cytotoxic T lymphocyte associated 4 soluble isoform included Cytotoxic T lymphocyte associated antigen 4 Cytotoxic T lymphocyte associated antigen 4 short spliced form Cytotoxic T lymphocyte associated protein 4 Cytotoxic T lymphocyte associated serine esterase 4 Cytotoxic T lymphocyte protein 4 Cytotoxic T-lymphocyte protein 4 Cytotoxic T-lymphocyte-associated antigen 4 GRD4 GSE ICOS IDDM12 insulin-dependent diabetes mellitus 12 Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4 OTTHUMP00000216623 |
Images
|
Fig1:
Advantages of using an Alpaca Recombinant Secondary 1. Smaller size Nanobodies are 1/10 the size of a traditional antibody (~15 kDa unconjugated). This means that the nanobody can penetrate tissue faster and deeper than other antibodies. 2. Easier to use Due to their simple structure, nanobodies also have the advantage of increased stability and ease of use. 3. Easier production When compared to a more traditional antibody, nanobodies are easier to develop and produce in the lab than monoclonal or polyclonal antibodies. 4. More consistent Since nanobodies are recombinantly produced from clonal DNA, you are guaranteed the same product every time. Comparatively, polyclonal antibodies are produced in live animals and have a very low lot-to-lot consistency while monoclonal antibodies can suffer from drift. 5. Higher Affinity Nanobodies benefit from consistently high binding affinity values. |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.